Company Overview and News

 
Zahid’s former press secretary, three others join Utusan board

2018-07-18 theedgemarkets
KUALA LUMPUR: Datuk Ibrahim Yahaya, former press secretary to former deputy prime minister Datuk Seri Dr Ahmad Zahid Hamidi, is among the four new board members of loss-making Utusan Melayu (Malaysia) Bhd.
5754 8362 8141 BSMAF 1818

 
Zahid Hamidi's former press sec, three others join Utusan board

2018-07-17 theedgemarkets
KUALA LUMPUR (July 17): Datuk Dr Ibrahim Yahaya, former press secretary to former deputy prime minister Datuk Seri Ahmad Zahid Hamidi, is among the four new board members for loss-making Utusan Melayu (Malaysia) Bhd.
5754 8362 8141 BSMAF 1818

 
Utusan appoints Zahid’s former press sec, three others as new directors

2018-07-17 thestar.com.my
KUALA LUMPUR: Utusan Melayu (M) Bhd , the newspaper publisher owned by Umno, has appointed four new independent directors following a shake-up in its boardroom.
5754 8362 8141

 
The Week Ahead: New Cabinet members, PNB chairman and Umno chief

2018-07-02 theedgemarkets
Malaysians will start the week with new members of the Cabinet being sworn in at Istana Negara on Monday (July 2). Before that, Umno will elect a new president over the weekend. Whoever wins the party election will have a big task ahead. He will have to find ways to improve the morale of members and regain the support of voters. The new chief will have to chart a new course for the political party.
8362 7121 0161

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...